Lung transplantation: Disease-specific considerations for referral

Chest

Volumn 127, Issue 3, 2005, Pages 1006-1016

  Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

COPD; Cystic fibrosis; Lung transplantation; Prognosis; Pulmonary fibrosis; Pulmonary hypertension; Sarcoidosis; Treatment outcome

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; HUMAN; LIFE EXPECTANCY; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MEDICAL DECISION MAKING; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SARCOIDOSIS; TREATMENT OUTCOME; EISENMENGER COMPLEX; INTERSTITIAL LUNG DISEASE; MORTALITY; PATIENT SELECTION; SURVIVAL RATE;

CYSTIC FIBROSIS; EISENMENGER COMPLEX; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS; QUALITY OF LIFE; REFERRAL AND CONSULTATION; SARCOIDOSIS, PULMONARY; SURVIVAL RATE;

EID: 15844394870     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.3.1006     Document Type: Article

References (79)

1. Sharples L, Belcher C, Dennis C. Who waits longest for heart and lung transplantation? J Heart Lung Transplant 1994; 13:282-291
2. The Scientific Registry of Transplant Recipients. Available at: http://www.ustransplant.org. Accessed February 24, 2005
3. Charman SC, Sharples LD, McNeil KD, et al. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21:226-232
4. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998; 351:24-27
5. The International Society for Heart and Lung Transplantation. Heart/Lung Transplant Registry. Available at: http:// www.ishlt.org/registries/slides.asp. Accessed February 24, 2005
6. Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286:2683-2689
7. Ramsey SD, Patrick DL, Lewis S, et al. Improvement in quality of life after lung transplantation: a preliminary study. J Heart Lung Transplant 1995; 14:870-877
8. Limbos MM, Joyce DP, Chan CK, et al. Psychological functioning and quality of life in lung transplant candidates and recipients Chest 2000; 118:408-416
9. Stavem K, Bjortuft O, Lund MB, et al. Health-related quality of life in lung transplant candidates and recipients. Respiration 2000; 67:159-165
10. Lanuza DM, Lefaiver C, Mc Cabe M, et al. Prospective study of functional status and quality of life before and after lung transplantation. Chest 2000; 118:115-122
11. Tenvergert VM, Essink-Bot ML, Geertsma A, et al. The effect of lung transplantation on health-related quality of life: a longitudinal study. Chest 1998; 113:358-364
12. American Society for Transplant Physicians, American Thoracic Society, European Respiratory Society, International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: the American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/ International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998; 158:335-339
13. O'Donnell DE, D'Arsigny C, Fitzpatrick M, et al. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med 2002; 166:663-668
14. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:544-549
15. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-1440
16. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797
17. Wilson DO, Rogers RM, Wright E, et al. Body weight in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1989; 139:1435-1438
18. Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:961-966
19. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1856-1861
20. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154:959-967
21. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124:459-467
22. 1-antitrypsin deficiency. Thorax 2003; 58:1020-1026
23. Schols AM, Buurman AJ, Staal-vd Brekel AJ, et al. Evidence for a relation between metabolic derangements and elevated inflammatory mediators in a subset of patients with chronic obstructive pulmonary disease. Thorax 1996; 51:819-824
24. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150:1453-1455
25. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073
26. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345-352
27. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
28. American Thoracic Society Statement. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
29. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345:1075-1083
30. Nathan SD, Edwards LB, Barnett SD, et al. Outcomes of COPD transplant recipients after lung volume reduction surgery. Chest 2004; 126:1569-1574
31. Daniil ZD, Gilchrit FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899-905
32. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203
33. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: die prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531-537
34. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548
35. Collard HR, King TE, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538-542
36. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233-238
37. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171-1181
38. Timmer SJ, Karamzadeh AM, Yung GL, et al. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia. Chest 2002; 122:779-784
39. Noon RA, Garrity ER. Lung transplantation for fibrotic diseases. Am J Med Sci 1998; 315:146-154
40. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962-969
41. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063-1072
42. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-a and -d as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19:439-446
43. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450-454
44. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164:103-108
45. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962-969
46. Perez A, Rogers RM, Dauber JH. The prognosis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29:819-826
47. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58:143-148
48. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090
49. Martinez FI, Bradford WZ, Safron S, et al. Rates and characteristics of death in patients with IPF [abstract]. Chest 2003; 124:1175
50. Travis WD, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and flbrosing patterns. Am J Surg Pathol 2000; 24:19-33
51. Katzenstein AL, Myers JL. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 1994; 18:136-147
52. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722-1727
53. Monaghan H, Wells AU, Colby TV, et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125:522-526
54. Katzenstein AL, Zisman DA, Litzky LA, et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002; 26:1567-1577
55. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-1191
56. Vizza CD, Yusen RD, Lynch JP, et al. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000; 162:819-825
57. Tantisira KG, Systrom DM, Ginns LC. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002; 165:1629-1633
58. Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56:746-750
59. Stanchina ML, Tantisira KG, Aquino SL, et al. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 2003; 21:217-225
60. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166:1550-1555
61. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345-352
62. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167:580-586
63. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 2002; 40:780-788
64. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. Circulation 2002; 106:1477-1482
65. Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998; 17:679-685
66. McLaughlin V, Sitbon O, Rubin LJ, et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med 2003; 167:A442
67. Barst RJ, Langleben D, Frost A, et al. STRIDE-1 Study Group: sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 2004; 169:441-447
68. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
69. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78:1207-1213
70. Hoeper MM, Galiè N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2001; 165:1209-1216
71. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115:343-349
72. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100-105
73. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
74. Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmengers syndrome. J Heart Lung Transplant 2002; 21:731-737
75. American Thoracic Society, the European Respiratory Society, the World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755
76. Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:154-158
77. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922-928
78. Studer SM, Krishnan JA, Orens JB. Indications for lung transplant referral: physician attitudes. J Heart Lung Transplant 2002; 21:716-717
79. United Network for Organ Sharing. Organ distribution. Available at: http://www.unos.org/PoliciesandBylaws/policies/docs/ policy_9.doc; accessed February 28, 2005